Gastrointestinal Cancer – Medical News Asia

Reporting HER2 IHC in 2026: CAP-Aligned Reporting Across Tumor Types and the Impact of Intratumoral Heterogeneity

REFINING HER2 IHC ASSESSMENT GUIDED BY CAP REPORTING TEMPLATE: ENABLING ACCURATE CLASSIFICATION ACROSS SOLID TUMORS AND ADDRESSING INTRATUMORAL HETEROGENEITY

24 June 2026/in Pantumor, Overexpression, HER2, HER2 Explorer, Breast Cancer, Gastrointestinal Cancer 2nd Homepage/by Reema Subramanian

The use of IHC staining of tissue samples to guide targeted treatment is widely used in clinical practice, and is recommended by expert groups for many tumor types and biomarkers. [11,12] The classical approach to IHC scoring for biomarkers, such as human epidermal growth factor receptor-2 (HER2), classifies specimens as either ‘positive’ or ‘negative’, scoring samples as IHC0, 1+, 2+ or 3+ per pathologists’ visual interpretation. [11,12]

Advances in Gastrointestinal Cancer Treatment: Insights from ASCO 2024

10 July 2024/0 Comments/in Gastrointestinal Cancer, Oncology In Depth/by Audrey TANG

Gastrointestinal (GI) cancers remain a global health challenge, with ongoing research continually seeking to improve diagnostic and therapeutic strategies. The American Society of Clinical Oncology (ASCO) 2024 conference showcased several groundbreaking studies that leverage technological advancements; this piece examines three critical studies from the conference, emphasising their contributions to the advancement of the field.

MHK-FOS-2024019 Case Sharing interview 1 KV

Managing Chemotherapy-Induced Nausea and Vomiting in Gastric Cancer Patients with NEPA and Reduced Dexamethasone

9 July 2024/in Therapeutic Areas, Gastrointestinal Cancer, Oncology, AE Management In Depth/by Jessica LAU

There is no excerpt because this is a protected post.

ASCO GI Webinar: Update on NET and HCC

7 October 2021/in Gastrointestinal Cancer, Oncology, ASCO 2021 Annual Meeting/by Kirsty LEE

There is no excerpt because this is a protected post.

ASCO 2021 Liver Cancer Update

11 June 2021/in Gastrointestinal Cancer, Oncology, ASCO 2021 Annual Meeting, Chemotherapy, Immunotherapy, Targeted Therapies/by Coco Chong

The liver cancer trials presented at American Society of Clinical Oncology (ASCO) 2021 were mainly focused on first-line treatments, with a few trials in the neoadjuvant, adjuvant and second-line setting.

Effect of prior therapy on BRAF V600E-mutant metastatic colorectal cancer

11 June 2021/in Gastrointestinal Cancer, Oncology, Targeted Therapies/by Coco Chong

An exploratory post-hoc analysis of the BEACON CRC study investigated the overall survival (OS) of encorafenib + cetuximab (doublet) and FOLFIRI (control) according to prior therapies (bevacizumab, oxaliplatin, FOLFOXIRI and anticancer therapy [ACT]) in BRAF V600E-mutant metastatic colorectal cancer (mCRC).

Cabotegravir and rilpivirine intramuscular combination safe in women

11 December 2020/0 Comments/in Gastrointestinal Cancer, Lung Cancer, Oncology, Targeted Therapies/by Kirsty LEE

Women account for a disproportionate percentage of new human immunodeficiency virus (HIV) infections in sub-Saharan Africa, comprising 59% of 18 million new adult HIV infections in 2017.

HCV-infected kidneys safe for transplantation with antiviral treatment

11 December 2020/0 Comments/in Gastrointestinal Cancer, Lung Cancer, Oncology, Targeted Therapies/by Kirsty LEE

Kidney transplants are the best treatment for end-stage renal disease (ESRD), with better survival outcomes than haemodialysis or peritoneal dialysis. However, in Hong Kong as well as much of the rest of the world, there is an increasing gap between the number of patients requiring a transplant and the number of organs available.

Baloxavir marboxil recommended as post-exposure prophylaxis to influenza by EMA

11 December 2020/0 Comments/in Gastrointestinal Cancer, Lung Cancer, Oncology, Targeted Therapies/by Kirsty LEE

Seasonal influenza is common between January to March, and July to August in Hong Kong. Baloxavir marboxil is the first influenza antiviral with a novel mechanism of action to be approved in almost two decades, and was registered for use in Hong Kong in February 2019.

U.S.-FDA-approved-immunecheckpoint-inhibitors-e1528902398517

US FDA approved immune-checkpoint inhibitors updated 08-Dec-2020

8 December 2020/19 Comments/in Gastrointestinal Cancer, Genitourinary Cancer, Gynaecological Cancer, Haematology, Head and Neck Cancer, Lung Cancer, Oncology, Melanoma & Skin Cancer, Immunotherapy, AE Management, irAE Management/by Stijn van den Borne, MSc

Know all the United States Food and Drug Administration (U.S. FDA) approved immune-checkpoint inhibitors. Members of MediPaper can download the free PPT slides summarising the U.S. FDA approved immune-checkpoint inhibitors and other U.S. FDA approved immunotherapies.